✨ Free AI Report
Ernexa Therapeutics (formerly Eterna Therapeutics): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Ernexa Therapeutics (formerly Eterna Therapeutics)
Company Research

Ernexa Therapeutics (formerly Eterna Therapeutics): Business Overview, Financials & Competitive Analysis

Ernexa Therapeutics develops innovative cell therapies for advanced cancer and autoimmune disease, with core technology focused on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells...

Analyst-debate audio for Ernexa Therapeutics (formerly Eterna Therapeutics)

AskCyborg analysts argue the bull and bear cases for Ernexa Therapeutics (formerly Eterna Therapeutics) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Early-stage cell therapy company with innovative platform but substantial clinical and financial runway...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Cell Therapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Ernexa Therapeutics (formerly Eterna Therapeutics) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Ernexa Therapeutics (formerly Eterna Therapeutics) Overview

Pro stress-test →

Ernexa Therapeutics develops innovative cell therapies for advanced cancer and autoimmune disease, with core technology focused on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) that provide scalable, off-the-shelf treatment solutions. The company changed its name from Eterna Therapeutics to Ernexa Therapeutics in March 2025 to reflect its strategic focus.

Strategic Profile

Pro stress-test →

Ernexa is developing two preclinical-stage cell therapy products: ERNA-101, designed to activate immune response against cancer cells, and ERNA-102, designed to target inflammation in autoimmune disease. The company is focused on advancing ERNA-101 for triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer.

Competitive Landscape

Pro stress-test →

Ernexa competes in the cell therapy space with companies like Juno Therapeutics (Celgene), Novartis (CAR-T), and other immunotherapy players. The allogeneic iMSC approach offers potential differentiation through scalable off-the-shelf production versus patient-specific therapies, but commercial success remains unproven in this highly competitive and capital-intensive sector.

Industry Context

Ernexa Therapeutics (formerly Eterna Therapeutics) operates in Biopharmaceuticals / Cell Therapy.

Key facts

Founded: 2018 · Headquarters: Cambridge, Massachusetts, United States · Revenue: $0 · Market cap: $2.6M - $9.5M (highly volatile)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Ernexa Therapeutics (formerly Eterna Therapeutics).

  • Recent name change (March 2025) signals strategic pivot to focus on specific cancer and autoimmune indications rather than platform approach
  • Company regained NASDAQ compliance in November 2024, resolving prior listing concerns
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Presented data at ASH Annual Meeting on cell therapy programs
  • May 2025Established Texas subsidiary to support ERNA-101 development and clinical operations
  • +2 moreTrack every material event for Ernexa Therapeutics (formerly Eterna Therapeutics) as it happens. Explore monitoring →
Get alerted when Ernexa Therapeutics (formerly Eterna Therapeutics) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyApproved genetically modified T-cell immunotherapies for blood cancers→Cell Therapy PlatformDeveloping cell therapies for blood cancers and solid tumors→Mesenchymal Stem Cell TherapiesEngineering cell therapies with focus on immune modulation→

Compare Ernexa Therapeutics (formerly Eterna Therapeutics) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Ernexa Therapeutics (formerly Eterna Therapeutics) operates in Biopharmaceuticals / Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Ernexa Therapeutics (formerly Eterna Therapeutics)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Ernexa Therapeutics (formerly Eterna Therapeutics) and its top competitor on Cyborg Score”
“What did Ernexa Therapeutics (formerly Eterna Therapeutics) do this quarter?”
“Is Ernexa Therapeutics (formerly Eterna Therapeutics) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Ernexa Therapeutics (formerly Eterna Therapeutics) do?+
Ernexa Therapeutics develops innovative cell therapies for advanced cancer and autoimmune disease, with core technology focused on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells...
What is Ernexa Therapeutics (formerly Eterna Therapeutics)'s Cyborg Score?+
Ernexa Therapeutics (formerly Eterna Therapeutics) has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Ernexa Therapeutics (formerly Eterna Therapeutics)'s main competitors?+
Named competitors include CAR-T Cell Therapy, Cell Therapy Platform, Mesenchymal Stem Cell Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Ernexa Therapeutics (formerly Eterna Therapeutics) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Ernexa Therapeutics (formerly Eterna Therapeutics) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Ernexa Therapeutics (formerly Eterna Therapeutics) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score